Patents Assigned to Elysium Therapeutics, Inc.
-
Patent number: 11318132Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.Type: GrantFiled: April 24, 2019Date of Patent: May 3, 2022Assignee: Elysium Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 11197933Abstract: The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.Type: GrantFiled: September 16, 2019Date of Patent: December 14, 2021Assignee: Elysium Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 11154549Abstract: The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.Type: GrantFiled: April 17, 2019Date of Patent: October 26, 2021Assignee: ELYSIUM THERAPEUTICS, INC.Inventor: Thomas E. Jenkins
-
Patent number: 11129825Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.Type: GrantFiled: February 26, 2019Date of Patent: September 28, 2021Assignee: ELYSIUM THERAPEUTICS, INC.Inventor: Thomas E. Jenkins
-
Patent number: 10335406Abstract: The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.Type: GrantFiled: October 26, 2017Date of Patent: July 2, 2019Assignee: Elysium Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 10314839Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.Type: GrantFiled: October 20, 2015Date of Patent: June 11, 2019Assignee: Elysium Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 10251878Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.Type: GrantFiled: August 22, 2017Date of Patent: April 9, 2019Assignee: Elysium Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 9808452Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.Type: GrantFiled: October 3, 2016Date of Patent: November 7, 2017Assignee: Elysium Therapeutics, Inc.Inventor: Thomas E. Jenkins